Boston Scientific (NYSE:BSX) might lack a truly leadless pacemaker, unlike rivals Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ), but it still might be in the best position to gain share in the cardiac rhythm management market, according to Leerink Swann analyst Danielle Antalffy.
Traditional pacemakers are inserted adjacent to the heart and use “leads” to deliver impulses to maintain regular heartbeat. St. Jude acquired a “leadless” pacemaker when it acquired Nanostim in October 2013, with Medtronic seeking approval for its own Micra version of the the technology.
Help employers find you! Check out all the jobs and post your resume.
